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Endocrinology and Metabolism

Relationship between Serum Testosterone and
Fracture Risk in Men:
A Comparison of RIA and LC-MS/MS
Thach S. Tran,1 Jacqueline R. Center,1,2 Markus J. Seibel,3 John A. Eisman,1,2,4,5 Mark M. Kushnir,6
Alan L. Rockwood,6 and Tuan V. Nguyen1,7,8*

BACKGROUND: Serum testosterone can be measured by
LC-MS/MS and RIA. We investigated whether the
testosterone–fracture relationship was affected by the
method of measurement.

testosterone and fracture risk in older men was largely
unaffected by the method of measurement.

METHODS: We measured total testosterone (TT) by LCMS/MS (TTLC-MS/MS) and RIA (TTRIA) in serum samples collected from 602 men whose incident fractures had
been continuously ascertained by x-ray reports from
1989 to 2010. We measured bone mineral density
(BMD) by dual-energy x-ray absorptiometry. The association between TT and fracture risk was assessed by the
Cox proportional hazards model, taking into account the
effect of age and BMD.

Measurement of testosterone is commonly used in the
diagnosis of androgen deficiency and epidemiologic
studies of association. It has been recommended that a
serum total testosterone (TT)9 concentration ⬍300
ng/dL (equivalent to 10.4 nmol/L) is considered hypogonadal (1 ). Recent epidemiologic studies have suggested
that hypogonadal concentrations of TT are associated
with an increased risk of fragility fracture (2, 3 ). In older
men from the Dubbo Study, after adjustment for major
risk factors, the risk of fracture was increased by 37% for
every 199 ng/dL (6.9 nmol/L) decrease in TT concentrations (3 ).
Serum testosterone can be measured by LC-MS/MS
and by immunoassay, including RIA, chemiluminescent
immunoassay, and enzyme-linked immunosorbent assay. Because of its lower cost and higher throughput, RIA
has been widely used in research and routine clinical
practice. However, the imprecision and accuracy of direct RIAs are usually suboptimal, in particular for measurements of low concentrations, which are clinically relevant (i.e., in women, children, and hypogonadal men)
(4 ). The correlation between RIA and LC-MS/MS for
measuring testosterone concentrations is high, with the
coefficient of correlation being ⬎0.9 (4 – 8 ). However,
discordance between commercial immunoassays and
mass spectrometry has been reported to be ⱕ5-fold at TT
concentrations of ⱕ230 ng/dL (7 ). Correlation is a
population-level measure, not necessarily applicable to
an individual. Thus it is not clear whether such a high

RESULTS:

Mean TTLC-MS/MS was higher than TTRIA
by 27 ng/dL (95% CI 13– 41). The concordance
correlation coefficient between TTLC-MS/MS and
TTRIA was 0.72 (95% CI 0.68 – 0.76). The Deming
regression equation linking the 2 measurements was
ln(TTLC-MS/MS ⫹ 10) ⫽ 0.87 ⫹ 0.87 ⫻ ln(TTRIA ⫹
10). The hazard ratio of fracture per SD decrease in
TT was 1.32 (95% CI 1.12–1.54) for TTLC-MS/MS and
1.23 (1.06 –1.43) for TTRIA. The correlation between
predicted probabilities of fracture by TTLC-MS/MS and
TTRIA was r ⫽ 0.96, with the mean difference being
0.01% (95% CI ⫺6.1% to 6.2%). Slightly more patients were classified as having hypogonadism if TTRIA
was used (29% vs 26%).
CONCLUSIONS: The concordance between LC-MS/MS
and RIA in the measurement of serum TT was moderate. Moreover, the magnitude of association between
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correlation could translate into an accurate classification
of hypogonadism for an individual.
From an epidemiologic point of view, measurements of TT by RIA methods are preferable given their
relatively lower cost and faster throughput. Nevertheless,
no data directly compare the ability of TT concentration
to predict future fracture risk as measured by RIA vs
LC-MS/MS. This study was designed to determine
whether the fracture–testosterone relationship was affected by the method of measurement at the population
and individual levels.
Materials and Methods
SETTING AND PARTICIPANTS

The study was part of the ongoing Dubbo Osteoporosis
Epidemiology Study, for which study design and protocols have been described in detail previously (3 ). Briefly,
through the electoral roll and via media campaign, all
men and women ⱖ60 years old as of June 30, 1989,
living in Dubbo (a regional city of 32 000 predominantly
white people in New South Wales, Australia) were invited to participate in the study. The age and sex distribution of the Dubbo population closely resembled that
of the general Australian population. The study was approved by St Vincent’s Hospital Ethics Review Committee, Sydney. Written informed consent was obtained
from all participants.
DATA COLLECTION

A nurse coordinator interviewed participants by administering a structured questionnaire to obtain anthropometric variables and other data including age,
history of fracture after 50 years of age, history of falls
in the preceding 12 months, lifestyle factors, and calcium intake. Bone mineral density (BMD) was measured at the lumbar spine and femoral neck by
dual-energy x-ray absorptiometry (Lunar DPX-L; GELunar). The same densitometer was used throughout
the study, and the CV for the BMD measurements was
1.3% and 5.3% at the lumbar spine and femoral neck,
respectively.
Incident fractures were continuously ascertained
from 1989 to 2010 by review of x-ray reports from all 3
radiological services for the entire Dubbo area. A study
coordinator determined the circumstances surrounding
each fracture by phone call after each fracture. The analysis included only low-trauma and nonpathologic fractures with a definite report of fracture. Fractures were
excluded from the analysis if they had clearly resulted
from major trauma (motor vehicle accidents) or underlying diseases (cancer or Paget disease) or were fractures
of digits, skull, or cervical spine.

LABORATORY MEASUREMENTS

We measured TT concentrations by LC-MS/MS
(TTLC-MS/MS) and RIA (TTRIA) in 602 (69.4%) of the
868 men who had been participating by July 2004 and
were followed up at biennial intervals. Men with and
without a serum sample (n ⫽ 259) were comparable with
regard to baseline characteristics, such as age, weight,
height, and BMD.
Most participants had nonfasting blood samples collected in the morning in plain tubes, which were centrifuged at 14 000g. Serum samples were removed and
stored in 2-mL Eppendorf tubes at ⫺80 °C until analysis. Serum TT concentrations were measured by LCMS/MS (9 ) at ARUP Laboratories. The same samples
were also measured by a commercial RIA (Delfia;
PerkinElmer, Wallac Oy) at the Bone Biology Laboratory, ANZAC Research Institute, Sydney. The limit of
quantification and method imprecision for TT were 3.0
ng/dL and ⬍10% (LC-MS/MS) and 8.6 ng/dL and
6.8% (RIA), respectively. Intraassay CVs were 5.6% and
4.5% for LC-MS/MS and RIA, respectively.
Serum concentrations of sex hormone– binding
globulin (SHBG) were determined by RIA (Delfia) at the
Bone Biology Laboratory, ANZAC Research Institute,
Sydney, with CVs of 10.2%, 5.3%, and 8.3% at high
(14.6 g/mL), mid-range (6.4 g/mL), and low (2.2
g/mL) concentrations, respectively. Estradiol concentrations were measured by LC-MS/MS (10 ) at ARUP
Laboratories. The limit of quantification for estradiol was
1.5 pg/mL (5.5 pmol/L), and method imprecision was
⬍10%.
STATISTICAL METHODS

We determined the extent of between-method agreement
in TT by comparing the measured values of TT obtained
by RIA with those obtained by LC-MS/MS as evaluated
by Deming regression (11 ) and Bland–Altman plot (12 ).
We used the  correlation coefficient (13 ) to quantify the
concordance in clinical diagnosis of male hypogonadism,
with a threshold of 300 ng/dL (10.4 nmol/L) (1 ).
We used the Cox proportional hazards model to
assess the association between TT and fracture risk. In
this method, the time to fracture was the outcome, and
measurements of TT were predictors. Two independent
models were considered: (a) fracture as a function of
TTRIA and (b) fracture as a function of TTLC-MS/MS. In
each model, we assessed the magnitude of association by
the hazard ratio and 95% CI per SD decrease in TT
concentration. The hazard ratio was further adjusted for
known risk factors, such as age, body weight, femoral
neck BMD, prior fracture, dietary calcium intake, SHBG
concentration, and smoking status. Femoral neck BMD
was considered in the model because it was less likely than
lumbar spine BMD to be affected by degenerative
changes. Because the distributions of testosterone conClinical Chemistry 61:9 (2015) 1183

centrations, SHBG, estradiol, and dietary calcium intake
were skewed, we applied a natural logarithmic (ln) transformation of observed values with the formula: ln(x ⫹ c),
where x is the original value and c is a normalized constant. A correlation of the predicted probability of fracture obtained from the 2 predictive models was determined. All statistical analyses were performed with the R
statistical environment on a Windows platform (14 ).

Table 1. Baseline characteristics of 602 participants
in the study.a
Variable

BETWEEN-METHOD AGREEMENT OF RIA AND LC-MS/MS
MEASUREMENTS

We evaluated data from 602 men aged 73 (6) years [mean
(SD)] whose serum TT concentrations were measured by
both RIA and LC-MS/MS (Table 1). Approximately
66% of men were age ⱖ70. TT concentrations were
weakly correlated with serum estradiol (Pearson correlation coefficient 0.45 for TTLC-MS/MS and 0.35 for
TTRIA) and SHBG (0.35 for TTLC-MS/MS and 0.36 for
TTRIA). Serum TTLC-MS/MS and TTRIA were 430 (206)
ng/dL [14.9 (7.1) nmol/L] and 403 (196) ng/dL [14
(6.8) nmol/L], respectively. The median (interquartile
range) of serum TTLC-MS/MS was 398 (296 to 555) ng/dL
[13.8 (10.3–19.2) nmol/L], and of serum TTRIA, 386
(280 to 525) ng/dL [13.4 (9.7–18.2) nmol/L]. Mean
TTRIA was lower than that of TTLC-MS/MS by 27 ng/dL
(0.9 nmol/L) [95% CI 13– 41, P (paired t-test) ⫽
0.0002]. The concordance correlation coefficient between the 2 methods of measurement was 0.72 (95% CI
0.68 – 0.76). There was no evidence that the betweenmethod difference was systematically related to the
means (Fig. 1). The Deming regression equation describing the relationship between TT concentration measured
by LC-MS/MS and RIA was ln(TTLC-MS/MS ⫹ 10) ⫽
0.87 ⫹ 0.87 ⫻ ln(TTRIA ⫹ 10). This equation suggested
that the RIA method overestimated TT concentrations
by 13% compared with the LC-MS/MS method (R2 ⫽
0.54). Free testosterone concentrations were estimated
from TT and SHBG concentrations with the empirical
algorithm proposed by Sartorius et al. (15 ). Free testosterone calculated from TTRIA was lower than that calculated from TTLC-MS/MS by 0.35 ng/dL [95% CI 0.17–
0.53, P (paired t-test) ⫽ 0.0002].
DIAGNOSTIC CONCORDANCE AT THE INDIVIDUAL LEVEL

With the criterion of TT ⱕ300 ng/dL (10.4 nmol/L),
156 men (26%) were classified as testosterone deficient
by LC-MS/MS (Table 2). With the same criterion, the
prevalence of testosterone deficiency was 29% (n ⫽ 176)
by RIA. However, the concordance in the diagnosis between 2 methods of measurement was modest, with a 
coefficient of 0.55 and  statistic of 0.57 (95% CI 0.47–
0.62). Among 156 men with testosterone deficiency by
TTLC-MS/MS, 45 (28.8%) were classified as eugonadal by
1184
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Age, years

72.59 (5.68)

Weight, kg

78.35 (12.93)

Height, cm

Results

Value

172.37 (6.32)

Body mass index, kg/m2

26.34 (3.79)

Dietary calcium, mg/day

635.62 (342.24)

Past or present smoker

356 (59.14)

Lumbar spine BMD, g/cm2

1.26 (0.22)

Lumbar spine T-score

0.48 (1.87)

Femoral neck BMD, g/cm2

0.91 (0.15)

Femoral neck T-score

−1.08 (1.28)

Serum TT measured by LC-MS/MS
ng/dL

430.17 (206.18)

nmol/L

14.93 (7.15)

Serum free testosterone calculated
from TTLC-MS/MS, ng/dLb
ng/dL

5.91 (2.53)

nmol/L

0.20 (0.09)

Serum TT measured by RIA, ng/dL
ng/dL

403.01 (195.53)

nmol/L

13.98 (6.78)

Serum free testosterone calculated
from TTRIA, ng/dLb
ng/dL

5.55 (2.45)

nmol/L

0.19 (0.08)

Serum estradiol
pg/mL

20.27 (9.32)

pmol/L

74.41 (34.21)

Serum SHBG
μg/mL

5.35 (2.30)

nmol/L

47.59 (20.46)

Previous fracture

112 (18.60)

a

Data are mean (SD) or n (%).
Free testosterone (pmol/L) = 24.00314 × TT/log10 SHBG − 0.04599 × TT2
[Sartorius et al. (15 )].
b

TTRIA. On the other hand, of the 446 men classified as
eugonadal by TTLC-MS/MS, 65 (14.6%) were considered
testosterone deficient by TTRIA. Slightly more patients
were classified as low testosterone if TTRIA was used,
regardless of the serum testosterone thresholds (Fig. 2).
CONCORDANCE IN THE MAGNITUDE OF THE ASSOCIATION
BETWEEN TT CONCENTRATION AND FRACTURE

During the median 7.8 years of follow-up, 112 men sustained a fragility fracture. The incidence of fracture was

Fracture Risk and Testosterone Measurement Methods

Fig. 1. TT measurement comparison between RIA and LC-MS/MS.
(A), Concordance correlation coefﬁcient between TTRIA concentration (x axis) and TTLC-MS/MS concentration (y axis). (B), Bland–Altman plot of the
mean ln(TT concentration) of the 2 methods (x axis) and percentage difference in ln(TT concentration) (y axis).
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Table 2. Concordance in the diagnosis of hypogonadism
between LC-MS/MS and RIA methods.a
Actual TTLC-MS/MS
Method

≤300 ng/dL

>300 ng/dL

Actual TTRIA
≤300 ng/dL

111 (0.71)a

65 (0.15)

>300 ng/dL

45 (0.29)

381 (0.85)

≤300 ng/dL

96 (0.61)

34 (0.08)

>300 ng/dL

60 (0.39)

412 (0.92)

Predicted TTLC-MS/MSb

a
b

Data are n (%).
Predicted TTLC-MS/MS was estimated by Deming equation: ln(TTLC-MS/MS + 10) =
0.87 + 0.87 × ln(TTRIA + 10).

3.4 per 100 person-years (95% CI 3.3–3.5). Most fractures occurred at the hip (26 ), vertebrae (44 ), and nonvertebrae (81 ). Men with fracture had a lower baseline
TT concentration than those without a fracture, measured by either LC-MS/MS [mean difference 35 ng/dL
(1.2 nmol/L); 95% CI ⫺7 to 77] or RIA [mean difference 45 ng/dL (1.6 nmol/L); 95% CI 5– 85]. The hazard
ratio of fracture per SD lower TT concentration was 1.23

(95% CI 1.06 –1.43) by RIA and 1.41 (1.19 –1.64) by
LC-MS/MS. The association between TT and fracture
risk remained statistically significant after adjusting for
SHBG, age, BMD, weight, and lifestyle factors (Table 3).
Similarly, every SD lower in calculated free testosterone
concentration, computed from TTLC-MS/MS and TTRIA,
was associated with a 25% and 22% increase in fracture
risk, respectively (see Supplemental Table 1, which accompanies the online version of this article at
http://www.clinchem.org/content/vol61/issue9).
On the basis of the association between TT and
fracture, we estimated the probabilities of any fracture,
hip fracture, vertebral fracture, and nonvertebral fracture with TTRIA (denoted by PRIA) and TTLC-MS/MS
(PLC-MS/MS). Fig. 3 shows the correlation between PRIA
and PLC-MS/MS. For each fracture site, the coefficient of
correlation between PRIA and PLC-MS/MS was consistently
⬎0.96, and the mean difference in the predicted probability of fracture was 0.01% (95% CI ⫺6.1% to 6.2%)
for any fracture.
Discussion
Accurate measurement of serum testosterone concentrations is essential for the diagnosis and management of
male hypogonadism (1 ). In this study, we used TT as a

Fig. 2. Concordance in the diagnosis of low testosterone between RIA and LC-MS/MS methods by different serum testosterone
thresholds.
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Table 3. Association between TT and fracture risk: analysis for TTLC-MS/MS and TTRIA.
TTLC-MS/MS

a

TTRIA

Hazard ratio (95% CI)a

P

Hazard ratio (95% CI)

Unadjusted

1.41 (1.19–1.64)

<0.001

1.23 (1.06–1.43)

0.006

Adjusted for SHBG

1.43 (1.23–1.67)

<0.001

1.37 (1.20–1.54)

<0.001

Adjusted for SHBG and age

1.28 (1.10–1.49)

0.002

1.12 (0.98–1.30)

0.1

Adjusted for SHBG, age, and weight

1.30 (1.11–1.52)

0.001

1.18 (1.02–1.37)

0.02

Adjusted for age, BMD, SHBG, weight, fracture history,
calcium intake, and smoking status

1.32 (1.12–1.54)

0.001

1.23 (1.06–1.43)

0.005

P

Estimated for every SD decrease of ln(TT concentration). The equivalent SD was 206 ng/dL for back-transformation.

predictor of fracture risk. We chose this predictor because
TT measurement is clinically recommended as both the
initial and the confirmed test for diagnosis of androgen
deficiency (1 ). Measurement of free or bioavailable testosterone is suggested for a subgroup of patients whose
TT concentrations are close to the lower limit of the
reference range (1 ), although its direct measurement is
costly, laborious, and not always possible in local laboratories. Furthermore, free testosterone calculated from TT
and SHBG concentrations was found to have excellent
predictive capability and very good performance (15 ).
Therefore, calculated free testosterone has been used in
most studies. At present, RIA and LC-MS/MS are commonly used for measuring TT, but it is not clear whether
the discordance between the 2 methods could affect the
classification of hypogonadism. In this study, we showed
that the correlation between TT concentrations determined by RIA and LC-MS/MS was reasonably high,
consistent with previous observations (5– 8 ). At the individual level, this correlation translated into some inconsistency in the classification of male hypogonadism
between the 2 methods of measurement, regardless of the
serum TT thresholds used. Nevertheless, at the population level, this had little effect on the predictive ability of
TT in terms of fracture risk.
The discordance between RIA and mass spectrometry in the measurement of serum testosterone could be
related to matrix effects and the functional sensitivity of
each method. Interfering substances or matrix effects
could substantially affect the imprecision of immunoassays without an extraction and chromatography component. Because 98% of circulating testosterone binds to
serum proteins (16 ), certain serum compounds that are
not removed from serum, especially SHBG, could interfere with the no-extraction immunoassays (17, 18 ). The
discordance could also result from antibody crossreactivity, inadequate limit of detection, or poor functional sensitivity of the immunoassays (7 ). Moreover, the
current testosterone immunoassays that use testosterone

analogs as standards have not been fully validated or standardized (19 ).
Excellent agreement between TTRIA and TTLC-MS/MS
has been reported (8 ), with correlation coefficients ranging from 0.92 for the automated multipurpose immunoassays from Bayer (Centaur) to 0.98 for a commercially
available RIA kit (DPC-RIA, Core Endocrine
Laboratory, Penn State University-Hershey Medical
Center). All methods except the DPC-RIA, however, had
an intercept of the Deming regression significantly different from that of LC-MS/MS, which is commonly considered a reference method. The inconsistency between
that study and ours could be a result of differences in the
population studied, RIA methods used, or method of
data analysis. The participants in the study of Wang et al.
(8 ) were much younger and less likely to have a low TT
concentration than our participants. Wang et al. (8 ) recruited 122 men, ages 18 – 68 years; meanwhile, all 602
elderly men in our study were age ⱖ60 years old, with a
mean age of 73 years. Aging is known to be associated
with decline in serum testosterone (20, 21 ). More importantly, whereas 29% of our participants had TT concentrations of ⱕ300 ng/dL, only 25 hypogonadal men in
Wang’s study had sera collected before testosterone therapy, a rate of 20%. The higher proportion of low TT
concentrations contributes positively to the betweenmethod discordance, since imprecision of RIAs increases
at lower TT concentrations (4, 6, 7 ). The mean ratio of
the concentrations of TTRIA to TTLC-MS/MS was 1.06 but
varied between 0.5 and 2.5 at low TT concentrations (6 ).
Similarly, disagreement between commercial immunoassays and mass spectrometry has been reported to be ⱕ5fold at TT concentrations ⬍230 ng/dL (7 ). The other
possible reason for the better agreement identified in the
Wang et al. study is method of analysis. All values that
were below the lower limit of quantification or statistical
outliers were excluded from their analysis, leaving 101
more centralized samples than ours.
Clinical Chemistry 61:9 (2015) 1187

Fig. 3. Correlation between predicted probabilities of fracture by TTLC-MS/MS and TTRIA concentration.

We found that, at the individual level, there was a
substantial discordance in the diagnosis of hypogonadism between RIA and LC-MS/MS. Indeed, the  statistic
was only 0.57, a little bit higher than chance agreement
(0.5).
We consider that the poor rate of agreement in the
diagnosis could be due to the loss of information when a
continuous variable is dichotomized (22 ), especially
when a cutpoint is selected arbitrarily (23 ). Statistically, a
population measure, i.e., a correlation coefficient, is not
necessarily applicable to an individual, since the former
1188
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focuses more on a mean than absolute values. On the
other hand, an absolute value of TT is used to diagnose
whether an individual is hypogonadal. Second, to fulfill
clinical classification of male hypogonadism, TT concentration is dichotomized by an arbitrary value. A threshold
of low TT concentration has long been controversial
(1, 4 ). The Endocrine Society Position Statement considered a TT concentration of ⱕ200 ng/dL as hypogonadal, whereas a TT concentration of 200 –320 ng/dL
was considered to be equivocal (4 ). In contrast, a TT
concentration of ⱖ346 ng/dL is reported as healthy in

Fracture Risk and Testosterone Measurement Methods

the European Association of Urology recommendation
(24 ). Without any strong biological plausibility background, a cutpoint of 300 ng/dL, which is the lower limit
of the reference range for TT concentrations in healthy
young men in some but not all laboratories (1 ), has been
recently used as a threshold of low testosterone. In our
study, a third of TT concentrations that fell within the
hypogonadal range turned out to be within reference intervals on repeat measurement (25 ), whereas a TT concentration below the reference range in a 24-h period was
reported in ⱖ15% of healthy young men (26 ). The imprecision of TT measurement, regardless of the laboratory method, emphasizes the need to confirm a low TT
concentration by repeat measurement before establishing
a diagnosis of hypogonadism for men with symptoms of
androgen deficiency (1 ).
An important contribution of this study is that the
discordance between TTLC-MS/MS and TTRIA had little
effect on the predicted probability of fractures. We found
that each SD decrease of TT concentration was associated with a 32% and 23% increase in fracture risk by
LC-MS/MS and RIA, respectively. However, the correlation between predicted probability of fracture on the
basis of TTRIA and TTLC-MS/MS was excellent (R ⱖ
0.96). More importantly, an absolute difference between
TTRIA and TTLC-MS/MS (27 ng/dL or 0.9 nmol/L) was
only 13% of an SD of TT concentrations, making the
between-method discordance very unlikely to alter the
testosterone–fracture relationship.
Emerging evidence suggests that apart from testosterone, estrogen also plays important roles in skeletal
maturation and mineralization in men (27–29 ). This has
some biologic basis, since the majority of estrogens in
elderly men are derived from androgens by peripheral
conversion (30 ). In our study, TT concentrations significantly correlated with serum estradiol (r ⫽ 0.45 for
TTLC-MS/MS and 0.35 for TTRIA) and SHBG (0.35 for
TTLC-MS/MS and 0.36 for TTRIA).
Our findings should be interpreted within the context of potential strengths and weaknesses. With 602 serum samples analyzed for TT determination by both RIA
and LC-MS/MS, this is the largest study ever conducted

to examine the accuracy of the immunoassays with mass
spectrometry as a reference method, using patient samples with available clinical information. In addition to the
robust design, a sufficiently large sample is known to
improve certainty of the findings. The study participants
had been followed for a reasonably long period, with
sufficient fracture incidence for a meaningful analysis. All
fractures that occurred within the studied period were
ascertained by x-ray reports. However, because serum
samples were not collected consistently in the morning, a
potential random measurement error could have occurred. This error, if any, would not significantly alter the
findings in our elderly cohort, since a circadian rhythm of
TT concentrations was reported to be absent in elderly
men (31 ).
In summary, these data show that there is a moderate
concordance in total testosterone measurements between
the RIA and LC-MS/MS methods (r ⫽ 0.72). Although
this moderate concordance could substantially misclassify the status of hypogonadism, it has little effect on the
prediction of fracture.
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